Financial News

Nicox Appoints Tomas Navratil, Ph.D., as Head of Development

Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), international ophthalmic company, today announced the appointment of Tomas Navratil, Ph.D., as Vice President and Head of Development, effective January 1, 2018. In this newly-created position, Dr. Navratil will be responsible for leading all of the Company’s non-clinical and clinical development activities, and will report to Michael Bergamini,

Read more

Nicox Recaps 2017 Achievements, Provides Update on Commercial Availability of VYZULTA and Outlines 2018 Activities

  • Nicox joins the select group of European R&D companies with U.S. FDA approved products, with two products approved in 2017
  • Valeant Pharmaceuticals International, Inc.’s wholly owned subsidiary, Bausch + Lomb, a leading global eye health company, announced yesterday that it has begun distributing VYZULTA™ (latanoprostene bunod ophthalmic solution), 0.024% to wholesale pharmaceutical distributors across the United States
  • VYZULTATM is the first approved product based on Nicox’s NO-donating research platform
  • Resources in 2018 will be focused on advancing Nicox’s pipeline candidates NCX 470 and NCX 4251 towards mid-stage clinical development and on progressing its next generation of discovery-stage NO-donating compounds targeting glaucoma into preclinical development

Sophia Antipolis,

Read more

Shareholder letter

November 6, 2017
Dear Nicox Shareholder,
It is an important moment for all of us, perhaps the most important since the foundation of Nicox.  The first drug generated by our proprietary NO-donating research platform has been approved for launch in the world’s largest, most prestigious and challenging pharmaceutical market, the United States.
As I am sure you are aware,

Read more
More news